Head to Head Comparison: Spectral AI (MDAI) & The Competition

Spectral AI (NASDAQ:MDAI) is one of 225 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare Spectral AI to related companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, risk and profitability.

Insider and Institutional Ownership

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 56.7% of Spectral AI shares are owned by company insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Spectral AI and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spectral AI	$18.06 million	-$20.85 million	-0.95
Spectral AI Competitors	$876.42 million	$48.15 million	-8.79

Spectral AI’s peers have higher revenue and earnings than Spectral AI. Spectral AI is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Spectral AI has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Spectral AI’s peers have a beta of 0.54, meaning that their average share price is 46% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Spectral AI and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	0	0	3	1	3.25
Spectral AI Competitors	1668	4413	8455	250	2.49

Spectral AI presently has a consensus price target of $4.50, suggesting a potential upside of 254.33%. As a group, “Surgical & medical instruments” companies have a potential upside of 19.18%. Given Spectral AI’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Spectral AI is more favorable than its peers.

Profitability

This table compares Spectral AI and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spectral AI	-89.85%	N/A	-104.64%
Spectral AI Competitors	-578.37%	-140.27%	-25.88%

Summary

Spectral AI beats its peers on 10 of the 13 factors compared.

Spectral AI Company Profile

Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.